Literature DB >> 21546495

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients.

Per Ljungman1, Rafael de la Camara, Lena Perez-Bercoff, Manuel Abecasis, Jose Bartolo Nieto Campuzano, M Jimena Cannata-Ortiz, Catherine Cordonnier, Hermann Einsele, Marta Gonzalez-Vicent, Ildefonso Espigado, Jörg Halter, Rodrigo Martino, Bilal Mohty, Gülsan Sucak, Andrew J Ullmann, Lourdes Vázquez, Katherine N Ward, Dan Engelhard.   

Abstract

During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective study was performed to collect data regarding risk factors and outcome of A/H1N1 in hematopoietic stem cell transplant recipients. Only verified pandemic A/H1N1 influenza strains were included: 286 patients were reported, 222 allogeneic and 64 autologous recipients. The median age was 38.3 years and the median time from transplant was 19.4 months. Oseltamivir was administered to 267 patients and 15 patients received zanamivir. One hundred and twenty-five patients (43.7%) were hospitalized. Ninety-three patients (32.5%) developed lower respiratory tract disease. In multivariate analysis, risk factors were age (OR 1.025; 1.01-1.04; P=0.002) and lymphopenia (OR 2.49; 1.33-4.67; P<0.001). Thirty-three patients (11.5%) required mechanical ventilation. Eighteen patients (6.3%) died from A/H1N1 infection or its complications. Neutropenia (P=0.03) and patient age (P=0.04) were significant risk factors for death. The 2009 A/H1N1 influenza pandemic caused severe complications in stem cell transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546495      PMCID: PMC3148919          DOI: 10.3324/haematol.2011.041913

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study.

Authors:  Deepali Kumar; Marian G Michaels; Michele I Morris; Michael Green; Robin K Avery; Catherine Liu; Lara Danziger-Isakov; Valentina Stosor; Michele Estabrook; Soren Gantt; Kieren A Marr; Stanley Martin; Fernanda P Silveira; Raymund R Razonable; Upton D Allen; Marilyn E Levi; G Marshall Lyon; Lorraine E Bell; Shirish Huprikar; Gopi Patel; Kevin S Gregg; Kenneth Pursell; Doug Helmersen; Kathleen G Julian; Kevin Shiley; Bartholomew Bono; Vikas R Dharnidharka; Gelareh Alavi; Jayant S Kalpoe; Shmuel Shoham; Gail E Reid; Atul Humar
Journal:  Lancet Infect Dis       Date:  2010-07-09       Impact factor: 25.071

2.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

Authors:  Anthony E Fiore; Timothy M Uyeki; Karen Broder; Lyn Finelli; Gary L Euler; James A Singleton; John K Iskander; Pascale M Wortley; David K Shay; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2010-08-06

3.  Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  P Ljungman; K N Ward; B N Crooks; A Parker; R Martino; P J Shaw; L Brinch; M Brune; R De La Camara; A Dekker; K Pauksen; N Russell; A P Schwarer; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2001-09       Impact factor: 5.483

4.  Serological response to influenza vaccine after hematopoetic stem cell transplantation.

Authors:  S Songül Yalçin; Meda Kondolot; Nurhan Albayrak; A Başak Altaş; Yasemin Karacan; Bariş Kuşkonmaz; Salih Aksu; Mualla Cetin; Hakan Göker; Kadriye Yurdakök; Duygu Uçkan
Journal:  Ann Hematol       Date:  2010-01-30       Impact factor: 3.673

5.  Morbidity of pandemic H1N1 influenza in children with cancer.

Authors:  Désirée Caselli; Francesca Carraro; Elio Castagnola; Ottavio Ziino; Stefano Frenos; Giuseppe Maria Milano; Susanna Livadiotti; Simone Cesaro; Nicoletta Marra; Giulio Zanazzo; Cristina Meazza; Monica Cellini; Maurizio Aricò
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

6.  Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients.

Authors:  Su-Mi Choi; Alexandre A Boudreault; Hu Xie; Janet A Englund; Lawrence Corey; Michael Boeckh
Journal:  Blood       Date:  2011-03-03       Impact factor: 22.113

7.  Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients.

Authors:  K Pauksen; A Linde; V Hammarström; J Sjölin; J Carneskog; G Jonsson; G Oberga; H Engelmann; P Ljungman
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

8.  The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.

Authors:  Dan Engelhard; Zichria Zakay-Rones; Michael Y Shapira; Igor Resnick; Diana Averbuch; Sigal Grisariu; Lillian Dray; Esther Djian; Nurith Strauss-Liviatan; Itamar Grotto; Dana G Wolf; Reuven Or
Journal:  Vaccine       Date:  2011-01-07       Impact factor: 3.641

9.  Severe novel influenza A (H1N1) infection in cancer patients.

Authors:  L A Hajjar; T Mauad; F R B G Galas; A Kumar; L F F da Silva; M Dolhnikoff; T Trielli; J P Almeida; M R L Borsato; E Abdalla; L Pierrot; R Kalil Filho; J O C Auler; P H N Saldiva; P M Hoff
Journal:  Ann Oncol       Date:  2010-05-28       Impact factor: 32.976

10.  Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

Authors:  Adrian R Tramontana; Biju George; Aeron C Hurt; Joseph S Doyle; Katherine Langan; Alistair B Reid; Janet M Harper; Karin Thursky; Leon J Worth; Dominic E Dwyer; C Orla Morrissey; Paul D R Johnson; Kirsty L Buising; Simon James Harrison; John F Seymour; Patricia E Ferguson; Bin Wang; Justin T Denholm; Allen C Cheng; Monica Slavin
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

View more
  44 in total

1.  Influenza virus resistance to neuraminidase inhibitors: implications for treatment.

Authors:  Shivanjali Shankaran; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

Review 2.  Clinical use of approved influenza antivirals: therapy and prophylaxis.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

3.  Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Roy F Chemaly; Amin M Alousi; Pankil K Shah; Gabriela Rondon; Lara Bashoura; Joumana Kmeid; Jacques Azzi; David W Blanco; Maryam Kaous; Burton F Dickey; Richard E Champlin; Dimpy P Shah
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

4.  Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

Authors:  A Ambati; L S V Boas; P Ljungman; L Testa; J F de Oliveira; M Aoun; V Colturato; M Maeurer; C M Machado
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

Review 5.  Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Authors:  Mini Kamboj; Monika K Shah
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

Review 6.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

7.  Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yusuke Fukatsu; Yasuyuki Nagata; Miwa Adachi; Tomohiro Yagyu; Takaaki Ono
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

8.  Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.

Authors:  Sung-Hoon Jung; Soo-Young Bae; Jae-Sook Ahn; Seung-Ji Kang; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Int J Hematol       Date:  2013-01-25       Impact factor: 2.490

9.  Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index.

Authors:  Joumana Kmeid; Jakapat Vanichanan; Dimpy P Shah; Firas El Chaer; Jacques Azzi; Ella J Ariza-Heredia; Chitra Hosing; Victor Mulanovich; Roy F Chemaly
Journal:  Biol Blood Marrow Transplant       Date:  2015-11-27       Impact factor: 5.742

10.  Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

Authors:  Sachiko Seo; Janet A Englund; Jack T Nguyen; Sasithon Pukrittayakamee; Niklas Lindegardh; Joel Tarning; Paul A Tambyah; Christian Renaud; Gregory T Went; Menno D de Jong; Michael J Boeckh
Journal:  Antivir Ther       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.